Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





Lab-Based COVID-19 PCR Tests Fail to Distinguish New ‘Stealth’ Version of Omicron from Other Variants

By LabMedica International staff writers
Posted on 09 Dec 2021

Omicron, the new SARS-CoV-2 variant, lacks a specific feature that allows PCR tests to distinguish probable cases among COVID-19 positive individuals, according to a report by The Guardian. More...

Scientists claim to have identified a “stealth” version of Omicron that cannot be distinguished from other SARS-CoV-2 variants using PCR tests utilized by public health officials to gain an understanding of its spread globally. The first Omicron (B.1.1.529) case was reported to the World Health Organization (WHO) on November 24. Just two days later, the WHO designated the variant a Variant of Concern (VOC), based on its unusually large number of mutations and early evidence of its spread. Despite a series of rapidly implemented travel bans, it has now been reported in Africa, many European countries, and a few in Asian countries.

The newly-discovered variant of Omicron shares several mutations with the standard Omicron, but lacks a specific genetic change that allows probable cases to be flagged by lab-based PCR tests. Most PCR machines look for three genes in the virus, although Omicron (and the prior variant Alpha) test positive on only two of these machines due to a genetic change called a deletion in the “S” or spike gene in both Omicron and Alpha. As a result of this glitch, PCR tests that display the so-called “S gene target failure” are highly suggestive of Omicron infections. The commonly used tests can still detect the stealth variant of Omicron as coronavirus, and genomic testing can identify it as the Omicron variant, although routine PCR tests that deliver quicker results can fail to flag probable cases.

Following the discovery of the new form of the Omicron variant, researchers have now split the B.1.1.529 lineage into standard Omicron, known as BA.1, and the newer variant, known as BA.2. Some researchers have now termed the new variant as “stealth Omicron” due to its lack of deletion that allows it to be spotted by PCR tests. Despite falling under Omicron, the stealth variant is so genetically distinct that it could qualify as a new VOC if it spreads rapidly. Researchers are worried over the arrival of two variants, BA.1 and BA.2, in quick succession with shared mutations that could indicate public health surveillance “is missing a big piece of the puzzle”.


Gold Member
Flu SARS-CoV-2 Combo Test
OSOM® Flu SARS-CoV-2 Combo Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Gold Member
Collection and Transport System
PurSafe Plus®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.